O	0	5	Three
O	5	6	-
O	6	9	Arm
O	10	20	Randomized
O	21	26	Phase
O	27	30	III
O	31	36	Trial
O	36	37	:
O	38	45	Quality
B-intervention	46	50	Aloe
I-intervention	51	54	and
I-intervention	55	62	Placebo
I-intervention	63	68	Cream
O	69	75	Versus
B-control	76	82	Powder
O	83	85	as
O	86	90	Skin
O	91	100	Treatment
O	101	107	During
O	108	114	Breast
O	115	121	Cancer
O	122	131	Radiation
O	132	139	Therapy
O	139	140	.

O	141	144	The
O	145	153	efficacy
O	154	156	of
O	157	161	aloe
O	162	169	extract
O	170	172	in
O	173	181	reducing
O	182	191	radiation
O	191	192	-
O	192	199	induced
O	200	204	skin
O	205	211	injury
O	212	214	is
O	215	228	controversial
O	228	229	.

O	230	233	The
O	234	241	purpose
O	242	244	of
O	245	248	the
O	249	256	present
O	257	258	3
O	258	259	-
O	259	262	arm
O	263	273	randomized
O	274	279	trial
O	280	283	was
O	284	286	to
O	287	291	test
O	292	295	the
O	296	304	efficacy
O	305	307	of
O	308	315	quality
O	315	316	-
O	316	322	tested
O	323	327	aloe
O	328	335	extract
O	336	338	in
O	339	347	reducing
O	348	351	the
O	352	360	severity
O	361	363	of
B-condition	364	373	radiation
I-condition	373	374	-
I-condition	374	381	induced
I-condition	382	386	skin
I-condition	387	393	injury
O	394	397	and
O	397	398	,
O	399	410	secondarily
O	410	411	,
O	412	414	to
O	415	422	examine
O	423	426	the
O	427	433	effect
O	434	436	of
O	437	438	a
O	439	444	moist
O	445	450	cream
O	451	457	versus
O	458	459	a
O	460	463	dry
O	464	470	powder
O	471	475	skin
O	476	480	care
O	481	488	regimen
O	488	489	.

O	490	491	A
O	492	497	total
O	498	500	of
B-total-participants	501	504	248
B-eligibility	505	513	patients
I-eligibility	514	518	with
I-eligibility	519	525	breast
I-eligibility	526	532	cancer
O	533	537	were
O	538	548	randomized
O	549	551	to
O	552	558	powder
O	558	559	,
O	560	564	aloe
O	565	570	cream
O	570	571	,
O	572	574	or
O	575	582	placebo
O	583	588	cream
O	588	589	.

O	590	595	Acute
O	596	600	skin
O	601	609	toxicity
O	610	613	was
O	614	620	scored
O	621	627	weekly
O	628	631	and
O	632	637	after
O	638	647	treatment
O	648	650	at
O	651	656	weeks
O	657	658	1
O	658	659	,
O	660	661	2
O	661	662	,
O	663	666	and
O	667	668	4
O	669	674	using
O	675	676	a
O	677	685	modified
O	686	688	10
O	688	689	-
O	689	694	point
O	695	704	Catterall
O	705	710	scale
O	710	711	.

O	712	715	The
O	716	724	patients
O	725	731	scored
O	732	737	their
O	738	745	symptom
O	746	754	severity
O	755	760	using
O	761	762	a
O	763	764	6
O	764	765	-
O	765	770	point
O	771	777	Likert
O	778	783	scale
O	784	787	and
O	788	792	kept
O	793	795	an
O	796	801	acute
O	802	807	phase
O	808	813	diary
O	813	814	.

O	815	818	The
O	819	823	aloe
O	824	835	formulation
O	836	839	did
O	840	843	not
O	844	850	reduce
B-outcome	851	856	acute
I-outcome	857	861	skin
I-outcome	862	870	toxicity
I-outcome	871	873	or
I-outcome	874	881	symptom
I-outcome	882	890	severity
O	890	891	.

O	892	900	Patients
O	901	905	with
O	906	907	a
O	908	915	greater
O	916	920	body
O	921	925	mass
O	926	931	index
O	932	936	were
O	937	941	more
O	942	948	likely
O	949	951	to
O	952	959	develop
B-outcome	960	965	acute
I-outcome	966	970	skin
I-outcome	971	979	toxicity
O	979	980	.

O	981	982	A
O	983	990	similar
O	991	998	pattern
O	999	1001	of
O	1002	1011	increased
B-outcome	1012	1016	skin
I-outcome	1017	1025	reaction
I-outcome	1026	1034	toxicity
O	1035	1043	occurred
O	1044	1048	with
O	1049	1053	both
O	1054	1059	study
O	1060	1066	creams
O	1067	1075	compared
O	1076	1080	with
O	1081	1084	the
O	1085	1088	dry
O	1089	1095	powder
O	1096	1103	regimen
O	1103	1104	.

O	1105	1107	No
O	1108	1116	evidence
O	1117	1120	was
O	1121	1126	found
O	1127	1129	to
O	1130	1137	support
O	1138	1150	prophylactic
O	1151	1162	application
O	1163	1165	of
O	1166	1173	quality
O	1174	1178	aloe
O	1179	1186	extract
O	1187	1189	or
O	1190	1195	cream
O	1196	1198	to
O	1199	1206	improve
O	1207	1210	the
O	1211	1219	symptoms
O	1220	1222	or
O	1223	1229	reduce
O	1230	1233	the
O	1234	1238	skin
O	1239	1247	reaction
O	1248	1256	severity
O	1256	1257	.

O	1258	1261	Our
O	1262	1269	results
O	1270	1277	support
O	1278	1279	a
O	1280	1283	dry
O	1284	1288	skin
O	1289	1293	care
O	1294	1301	regimen
O	1302	1304	of
O	1305	1311	powder
O	1312	1318	during
O	1319	1328	radiation
O	1329	1336	therapy
O	1336	1337	.
